Tag: formulation

Managing Regulatory Risks Related to Inadequate Control Strategies During Pilot Scale Operations In the realm of pharmaceutical manufacturing, pilot scale operations are a crucial step in the journey from formulation…

Mitigating Risks of Inadequate Control Strategies During Development Studies Pharmaceutical professionals involved in formulation and process development are frequently faced with the challenge of ensuring that their control strategies meet…

Strategies for Addressing Poorly Defined CPPs in Development Studies In the realm of pharmaceutical development, the inadequacy of Critical Process Parameters (CPPs) can lead to significant challenges, particularly during scale-up…

Minimizing Regulatory Scrutiny Risks When CPPs are Poorly Defined In the pharmaceutical manufacturing landscape, it is increasingly crucial to ensure that Critical Process Parameters (CPPs) are well-defined throughout the regulatory…

Aligning Critical Process Parameters During Lifecycle Optimization in Pharma In the fast-paced world of pharmaceutical manufacturing, failure to clearly define Critical Process Parameters (CPPs) during lifecycle optimization can lead to…

Improving Process Robustness Amid Yield Loss in Pilot Scale Optimization Yield loss during optimization in pilot scale operations poses significant challenges for pharmaceutical companies. Each incidence of yield loss not…

Strategic Approaches for Addressing Poor Justification of Design Space During Validation Planning In the pharmaceutical industry, the successful transition from formulation development to commercial production hinges on a well-defined design…

Improving Process Robustness: Addressing Poor Justification of Design Space in Regulatory Submissions In the evolving landscape of pharmaceutical manufacturing, one recurring challenge is the inadequate justification of the design space…

Framework for Enhancing Process Robustness: Addressing Inadequate Control Strategies During Regulatory Submissions Inadequate control strategies during regulatory submissions can lead to significant process challenges and compliance risks for pharmaceutical manufacturers.…

Understanding the Impact of Poorly Defined CPPs on Regulatory Submissions In the pharmaceutical industry, the significance of well-defined Critical Process Parameters (CPPs) during regulatory submissions cannot be overstated. CPPs are…

Addressing Insufficient Control Strategies During Development Studies During the lifecycle of pharmaceutical products, an inadequately designed control strategy can lead to significant regulatory hurdles and product quality issues. This article…

Managing Yield Loss During Optimization in Pilot Scale: A Playbook for Regulatory Scrutiny Mitigation Yield loss during optimization in pilot scale processes can pose significant risks for pharmaceutical manufacturers aiming…